Prior exposure to AAV-CNGA3 or AAV-CNGB3

Pre-clinicalTerminated

0 views this week 0 watching💤 Quiet

Interest: 12/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Achromatopsia

Conditions

Achromatopsia

Trial Timeline

Jun 29, 2017 → Apr 4, 2024

NCT ID

NCT03278873

About Prior exposure to AAV-CNGA3 or AAV-CNGB3

Prior exposure to AAV-CNGA3 or AAV-CNGB3 is a pre-clinical stage product being developed by MeiraGTx for Achromatopsia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03278873. Target conditions include Achromatopsia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03278873	Pre-clinical	Terminated	Jun 29, 2017	Apr 4, 2024	Achromatopsia

Competing Products

2 competing products in Achromatopsia

See all competitors

Product	Company	Stage	Hype Score
AAV - CNGB3	MeiraGTx	Phase 1/2	26
adeno-associated virus vector AAV- CNGA3	MeiraGTx	Phase 1/2	26